Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC. Odintsov I et al.J Thorac Oncol. 2023 D…
この記事を読む
一臨床医の勉強のための備忘録です。間違いなどあればご指摘を頂ければ幸いです。
この記事を読む
Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC. Odintsov I et al.J Thorac Oncol. 2023 D…
この記事を読む
Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-…
この記事を読む
Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer. Wu YL et al.N Engl J Med. 2024 Apr 11;390(14):1265-1276.P…
この記事を読む
Phase Ⅲ, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Sm…
この記事を読む
Lack of Association Between Immunotherapy and Improvement of Survival for Non-small Cell Lung Cancer Patients With Hemod…
この記事を読む
Correlations of response rate and progression-free survival with overall survival in immunotherapy trials for metastatic…
この記事を読む
Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathological and prognostic analysis of 35 cases and immunot…
この記事を読む
Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. Wang K et al.J Thorac Oncol. 2024 Mar;19(3):500-506…
この記事を読む
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osi…
この記事を読む
Primary Spontaneous Pneumothorax (Clinical Decisions) Smyth R et al.N Engl J Med 2024;390:666-668 症例提示30歳の男性が、急な右側胸部痛と軽度…